Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG)

Langenbeck's Archives of Surgery

Volumn 398, Issue 7, 2013, Pages 973-981

  Sisic, Leila ^a   Blank, Susanne ^a   Weichert, Wilko ^a   Jäger, Dirk ^a   Springfeld, Christoph ^a   Hochreiter, Marcel ^a   Büchler, Markus ^a   Ott, Katja ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Adenocarcinoma of the esophagogastric junction (AEG); Extent of lymphadenectomy; Lymph node involvement; Lymph node ratio (LNR); Number of lymph nodes removed; Prognosis

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; LUNG DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRACHEOTOMY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84885577102     PISSN: 14352443     EISSN: 14352451     Source Type: Journal    
DOI: 10.1007/s00423-013-1101-6     Document Type: Article

References (40)

1. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12(7):681-692. doi: 10.1016/S1470-2045(11)70142-5
2. Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH (2009) Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol 15(47):5983-5991
3. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715-1721
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11-20. doi: 10.1056/NEJMoa055531
5. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27(30):5062-5067. doi: 10.1200/JCO.2009.22.2083
6. Siewert J, Feith M, Werner M, Stein HJ (2000) Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 232(3):353-361
7. Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V (2006) The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 132(6):1374-1381. doi: 10.1016/j.jtcvs.2006.07.039
8. Korst RJ, Rusch VW, Venkatraman E, Bains MS, Burt ME, Downey RJ, Ginsberg RJ (1998) Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 115(3):660-669, Discussion 669-670
9. Rice TW, Blackstone EH, Rybicki LA, Adelstein DJ, Murthy SC, DeCamp MM, Goldblum JR (2003) Refining esophageal cancer staging. J Thorac Cardiovasc Surg 125(5):1103-1113. doi: 10.1067/mtc.2003.170
10. Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Swisher SG, Watson TJ, Blackstone EH (2009) Worldwide esophageal cancer collaboration. Dis Esophagus 22(1):1-8
11. Rice TW, Rusch VW, Ishwaran H, Blackstone EH (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 116(16):3763-3773. doi: 10.1002/cncr.25146
12. Gu Y, Swisher SG, Ajani JA, Correa AM, Hofstetter WL, Liao Z, Komaki RR, Rashid A, Hamilton SR, Wu TT (2006) The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer 106(5):1017-1025. doi: 10.1002/cncr.21693
13. Bollschweiler E, Baldus SE, Schroder W, Schneider PM, Holscher AH (2006) Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 94(5):355-363. doi: 10.1002/jso.20569
14. Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP (2008) Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 112(6):1239-1246. doi: 10.1002/cncr.23309
15. Peyre CG, Hagen JA, DeMeester SR, Altorki NK, Ancona E, Griffin SM, Holscher A, Lerut T, Law S, Rice TW, Ruol A, van Lanschot JJ, Wong J, DeMeester TR (2008) The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 248(4):549-556. doi: 10.1097/SLA.0b013e318188c474
16. Schwarz RE, Smith DD (2007) Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 11(11):1384-1393. doi: 10.1007/s11605-007-0264-2, discussion 1393-1384
17. Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Hofstetter WL, Watson TJ, Allen MS, Rusch VW, Blackstone EH (2010) Optimum lymphadenectomy for esophageal cancer. Ann Surg 251(1):46-50. doi: 10.1097/SLA.0b013e3181b2f6ee
18. Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP (2008) Prognostic significance of the number of lymph node metastases in esophageal cancer. J Am Coll Surg 206(2):239-246. doi: 10.1016/j.jamcollsurg. 2007.09.003
19. Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR (1995) Prognostic factors of resected adenocarcinoma of the esophagus. Surgery 118(5):845-855
20. Lagarde SM, ten Kate FJ, de Boer DJ, Busch OR, Obertop H, van Lanschot JJ (2006) Extracapsular lymph node involvement in node-positive patients with adenocarcinoma of the distal esophagus or gastroesophageal junction. Am J Surg Pathol 30(2):171-176
21. Mariette C, Piessen G, Briez N, Triboulet JP (2008) The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 247(2):365-371
22. van Sandick JW, van Lanschot JJ, ten Kate FJ, Tijssen JG, Obertop H (2002) Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg 194(1):28-36
23. Wijnhoven BP, Tran KT, Esterman A, Watson DI, Tilanus HW (2007) An evaluation of prognostic factors and tumor staging of resected carcinoma of the esophagus. Ann Surg 245(5):717-725. doi: 10.1097/01.sla.0000251703.35919.02
24. Ott K, Bader FG, Lordick F, Feith M, Bartels H, Siewert JR (2009) Surgical factors influence the outcome after Ivor-Lewis esophagectomy with intrathoracic anastomosis for adenocarcinoma of the esophagogastric junction: a consecutive series of 240 patients at an experienced center. Ann Surg Oncol 16(4):1017-1025. doi: 10.1245/s10434-009-0336-5
25. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M (2008) Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg 248(2):221-226. doi: 10.1097/SLA.0b013e31817bbe59
26. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF (2007) Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol 14(2):306-316. doi: 10.1245/s10434-006-9166-x
27. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM (2002) Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 95(7):1434-1443. doi: 10.1002/cncr.10868
28. Gockel I, Heckhoff S, Messow CM, Kneist W, Junginger T (2005) Transhiatal and transthoracic resection in adenocarcinoma of the esophagus: does the operative approach have an influence on the long-term prognosis? World J Surg Oncol 3:40. doi: 10.1186/1477-7819-3-40
29. Law S, Wong J (2007) Lymph node dissection in surgical treatment of esophageal neoplasms. Surg Oncol Clin N Am 16(1):115-131. doi: 10.1016/j.soc.2006.10.008
30. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van Lanschot JJ (2002) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347(21):1662-1669
31. D'Journo XB, Doddoli C, Michelet P, Loundou A, Trousse D, Giudicelli R, Fuentes PA, Thomas PA (2005) Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg 27(4):697-704. doi: 10.1016/j.ejcts.2004.12.022
32. Johansson J, DeMeester TR, Hagen JA, DeMeester SR, Peters JH, Oberg S, Bremner CG (2004) En bloc vs transhiatal esophagectomy for stage T3 N1 adenocarcinoma of the distal esophagus. Arch Surg 139(6):627-631. doi: 10.1001/archsurg.139.6.627, discussion 631-623
33. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR (2001) Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 234(4):520-530, discussion 530-521
34. Putnam JB Jr, Suell DM, McMurtrey MJ, Ryan MB, Walsh GL, Natarajan G, Roth JA (1994) Comparison of three techniques of esophagectomy within a residency training program. Ann Thorac Surg 57(2):319-325
35. Altorki NK, Girardi L, Skinner DB (1997) En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg 114(6):948-955, discussion 955-946
36. Sihvo EI, Luostarinen ME, Salo JA (2004) Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 99(3):419-424. doi: 10.1111/j.1572-0241.2004.04094.x
37. Rentz J, Bull D, Harpole D, Bailey S, Neumayer L, Pappas T, Krasnicka B, Henderson W, Daley J, Khuri S (2003) Transthoracic versus transhiatal esophagectomy: a prospective study of 945 patients. J Thorac Cardiovasc Surg 125(5):1114-1120. doi: 10.1067/mtc.2003.315
38. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH (2007) Lymphadenectomy extent is closely related to long-term survival in esophageal cancer. Eur J Cardiothorac Surg 31(2):154-160. doi: 10.1016/j.ejcts.2006.10.033
39. Peyre CG, Hagen JA, DeMeester SR, Van Lanschot JJ, Holscher A, Law S, Ruol A, Ancona E, Griffin SM, Altorki NK, Rice TW, Wong J, Lerut T, DeMeester TR (2008) Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 248(6):979-985. doi: 10.1097/SLA.0b013e3181904f3c
40. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ (2007) Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 246(6):992-1000. doi: 10.1097/SLA.0b013e31815c4037, discussion 1000-1001